Introducing CORAL, a neurology research consortium using Olink data

Neurology , Proteomics
Tuesday 24 August 2021
Read time: 5 minutes

In its mission to accelerate proteomics together, Olink encourages the advancement of science through comprehensive support of its customers in their own studies to achieve better insight into their areas of research. Sometimes, this may be achieved through collaboration with other scientists in their fields.

As a result, Olink has played a part in creating several consortia involving Olink customers with similar areas of interest, such as SCALLOP, where like-minded researchers work together to publish high-impact papers investigating the association of genes and proteins included in Olink protein panels.

Such was the case for Olink’s neurology customers. Seeing a need for more collaboration between them, Olink reached out to Charlotte Teunissen to chair a new consortium where Olink neurology researchers from pharma and academia may collaborate in different workgroups and projects to advance their research questions with Olink data at its heart. Together with postdoctoral fellow Dr. Lisa Vermunt, Professor Teunissen is driving this initiative, with administrative support from Olink.

CORAL brings biomarker research to neurology

The purpose of the CORAL consortium is to explore and identify novel biomarkers and biological mechanisms for neurological diseases, with the aim that they may be used for diagnostic, monitoring, and/or treatment response. Using Olink protein biomarker data as a base, PIs from all over the world using pioneering technologies and methods will work together in CORAL neurology studies and research initiatives. Combining and sharing data also adds strength and statistical power, greatly expanding sample sizes for studies as well as allowing PIs to learn and conduct complex analyses that may not be possible alone.

The CORAL neurology kick-off meeting

The CORAL consortium initiative began with a kick-off meeting on the 22nd of July 2021, with the purpose of gathering interested neurology researchers with Olink data to discuss the structure and organization of the consortium, as well as attendees’ expectations, preferences, and ideas. Dr. Teunissen chaired the meeting and presented the initiative and her ideas for how the consortium may work going forward, with the intention to hear the panel’s responses, feedback, and work on agreements and possible collaborations between the researchers who attended.

The kick-off meeting began with a short introduction to Olink and its role in the consortium by Anne-Li Lind, the scientific liaison for neuroscience at Olink, who will coordinate Olink’s support for CORAL. Olink’s role in the consortium will be purely supportive and promotive, and Olink will not own or have access to any CORAL data. Professor Teunissen and her team will lead CORAL and decide which support is needed from Olink to run the consortium successfully.

Limitations may be overcome with the sharing of data and collaboration between consortium members

Lisa Vermunt, the coordinator of the consortium, gave a presentation on CORAL, and how she and Dr. Teunissen see opportunities for collaboration in CORAL. Such opportunities exist in all steps of the process from biomarker discovery to clinical implementation. In summary, many biomarker studies suffer from a lack of strength, with regards to small datasets, statistical analysis, lack of population cohorts, and the inability to replicate analyses in a more diverse patient cohort. They hope that by establishing CORAL, such limitations may be overcome with the sharing of data and collaboration between consortium members.

The meeting then moved to a round-table discussion involving the attending researchers, who included researchers from Dr. Teunissen’s network as well as Olink’s neurology and neuroscience contacts. Overall, attendees were optimistic and supportive of the consortium and the opportunity to collaborate in their research, and several ideas for project collaboration were suggested.

Join us!

If you are a neuroscience researcher with shareable Olink data and wish to join CORAL, visit the CORAL website to learn more.

CORAL

How the proteome behaves in healthy individuals

Clinical research, Multiomics
To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations.

Key proteomics publications from 2020

Proteomics
Welcome to the first post of the all-new weekly Olink to Science! Our customer survey revealed that you would like to know more about the many publications, research, and other science happening at Olink, therefore this blog aims to do just that: keep you informed on the exciting science taking place with our technology.

Protein biomarkers are crucial in early detection of cancer

Clinical research, Oncology, Protein biomarkers
A central premise of precision medicine is to identify biomarkers indicative of disease transitions early on. This is especially important in cancer where early treatment intervention could increase a patient’s chance of survival and reduce the probability of cancer recurrence.

Using PEA and RNA-Seq to study disease pathology

Clinical research, Proteomics
The following study illustrates how transcriptomics and proteomics complement one another to clarify the pathology of a complex, and little understood disease. Atopic dermatitis (AD) is the most common chronic skin condition affecting up to 20% of children and 7-10% of adults, depending on the population.

Olink protein biomarker panel indicates fermented foods fight inflammation

Inflammation, Proteomics
Could food be used to fight chronic disease?

Study identifies proteins involved in immunotherapy response

Oncology, Proteomics
'Ultimately, it is all about understanding and treating patients better in the future.'

Proteins diagnostic of lung cancer up to 5 years before disease onset

Oncology
An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.

Utilizing proteogenomics technology for novel drug target discovery

Drug discovery & development
High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation.

Developing a high-performance biomarker panel for Alzheimer’s disease

Clinical research, Neurology, Protein biomarkers
A simple search of the term ‘scourge of Alzheimer’s Disease’ brings up over half a million website hits. A major disease, about 15% of us that reach the age of 67 to 74, and 44% of those 75 to 84 will develop AD.

How proteomics helped diabetic kidney disease research advance

Clinical research, Proteomics
Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.

2947

Biomarker assays

~881 million

Protein data points generated

1182

Publications listed on website